Page 35 - Dan Budwick News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Centessa Pharmaceuticals plc: Centessa Announces Pricing of Initial Public Offering Centessa Pharmaceuticals plc ("Centessa"), a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, announced today the pricing of its initial public offering of 16,500,000 American Depositary Shares ("ADSs"), each representing one ordinary share at a public offering price of $20.00 per ADS. All of the ADSs are being offered by Centessa. The gross proceeds to Centessa from the offering, before deducting underwrit...

Share: CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the 2021 Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 9:30 a.m. ET. The live webcast will be available in the investor section of the company's website at www.beamtx.com. The webcast will be archived for 60 days following the presentation. About Beam Therapeutics Beam Therapeutics (NASDAQ:BE...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

(0) Centessa Pharmaceuticals ("Centessa") today announced that Antoine Yver, M.D., M.Sc., has been appointed as Chief Medical Officer. Dr. Yver is one of the world's leading drug developers with more than 30 years of global experience in the pharmaceutical industry. "We are absolutely thrilled to welcome Antoine to our team as CMO," said Saurabh Saha, M.D., Ph.D., Chief Executive Officer of Centessa. "Antoine is a true industry leader with significant experience and success as a drug developer, having developed some of the most impactful oncology drugs in the world. I look forward to partneri...

Nektar Therapeutics Reports First Quarter 2021 Financial Results News provided by Share this article Share this article SAN FRANCISCO, May 6, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2021. Cash and investments in marketable securities at March 31, 2021 were approximately $1.1 billion as compared to $1.2 billion at December 31, 2020. "We continue to build momentum with our clinical pipeline of novel cytokine therapeutics," said Howard W. Robin, President and CEO of Nektar. "We have a robust development...